Assembly Biosciences (NASDAQ:ASMB) Stock Price Passes Above 200 Day Moving Average of $10.92

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.92 and traded as high as $13.90. Assembly Biosciences shares last traded at $13.41, with a volume of 11,396 shares.

Wall Street Analyst Weigh In

ASMB has been the topic of several analyst reports. StockNews.com upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Friday, April 5th. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a report on Monday, April 1st.

Assembly Biosciences Price Performance

The company has a 50-day moving average price of $12.93 and a two-hundred day moving average price of $10.92. The company has a market cap of $73.49 million, a PE ratio of -0.79 and a beta of 0.57.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ASMB. Acuitas Investments LLC acquired a new position in shares of Assembly Biosciences in the fourth quarter worth about $218,000. Renaissance Technologies LLC raised its stake in Assembly Biosciences by 52.1% during the first quarter. Renaissance Technologies LLC now owns 765,800 shares of the biopharmaceutical company’s stock valued at $644,000 after buying an additional 262,416 shares in the last quarter. Vanguard Group Inc. raised its stake in Assembly Biosciences by 4.4% during the fourth quarter. Vanguard Group Inc. now owns 2,339,088 shares of the biopharmaceutical company’s stock valued at $1,918,000 after buying an additional 99,092 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Assembly Biosciences by 123.6% during the first quarter. Goldman Sachs Group Inc. now owns 123,772 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 68,411 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in Assembly Biosciences by 587.6% during the fourth quarter. Jane Street Group LLC now owns 76,961 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 65,768 shares in the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.